The effect of paclitaxel powder on glaucoma filtration surgery in rabbits.
OBJECTIVE
The authors determine if the intraoperative placement of paclitaxel powder in the subconjunctival space improves the outcome of glaucoma filtration surgery in rabbits.


METHODS
A posterior lip sclerectomy was performed in the right eye of 24 New Zealand white rabbits. Before the conjunctiva was fully sutured, 8 mg of mannitol powder alone, or 8 mg of mannitol powder containing either 10 micrograms or 250 micrograms of paclitaxel, was placed in the subconjunctival space of six eyes each in masked fashion. An additional six animals were treated with episcleral application of a sponge soaked in a solution of 0.5 mg/ml of mitomycin C (MMC) for 5 minutes before the sclerectomy was performed. Intraocular pressure and bleb size were measured until the operation had failed or until the 7 weeks of observation had concluded.


RESULTS
Both paclitaxel powder and MMC solution improved the outcome of filtration surgery in this model as measured by magnitude of intraocular pressure (IOP) lowering and duration of surgical success. No toxic effect of either drug was observed, although endophthalmitis was observed in eight animals followed for more than 3 weeks.


CONCLUSIONS
The introduction of paclitaxel into the subconjunctival space at the conclusion of filtration surgery has an effect comparable to intraoperative MMC.
Jampel
H D
HD
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Moon
J I
JI
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000494:pharmacology*; D003228:Conjunctiva; D018463:Filtering Surgery; D005901:Glaucoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D007429:Intraocular Pressure; D007432:Intraoperative Period; D016685:Mitomycin / Q000008:administration & dosage; D009883:Ophthalmic Solutions; D017239:Paclitaxel / Q000009:adverse effects / Q000494:pharmacology*; D011208:Powders; D011817:Rabbits; D011897:Random Allocation; D012590:Sclera / Q000187:drug effects* / Q000473:pathology; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D009883:Ophthalmic Solutions; D011208:Powders; D016685:Mitomycin; D017239:Paclitaxel